| Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia GG Kenter, MJP Welters, ARPM Valentijn, MJG Lowik, ... New England Journal of Medicine 361 (19), 1838-1847, 2009 | 1278 | 2009 |
| Therapeutic cancer vaccines M Saxena, SH van der Burg, CJM Melief, N Bhardwaj Nature Reviews Cancer 21 (6), 360-378, 2021 | 760 | 2021 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 737 | 2019 |
| High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma C Linnemann, MM Van Buuren, L Bies, EME Verdegaal, R Schotte, ... Nature medicine 21 (1), 81-85, 2015 | 734 | 2015 |
| Vaccines for established cancer: overcoming the challenges posed by immune evasion SH van der Burg, R Arens, F Ossendorp, T van Hall, CJM Melief Nature Reviews Cancer 16 (4), 219-233, 2016 | 708 | 2016 |
| Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines CJM Melief, SH Van Der Burg Nature Reviews Cancer 8 (5), 351-360, 2008 | 692 | 2008 |
| Therapeutic cancer vaccines CJM Melief, T van Hall, R Arens, F Ossendorp, SH van der Burg The Journal of clinical investigation 125 (9), 3401-3412, 2015 | 653 | 2015 |
| A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence J Kaplon, L Zheng, K Meissl, B Chaneton, VA Selivanov, G Mackay, ... Nature 498 (7452), 109-112, 2013 | 626 | 2013 |
| Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides S Zwaveling, SCF Mota, J Nouta, M Johnson, GB Lipford, R Offringa, ... The Journal of Immunology 169 (1), 350-358, 2002 | 575 | 2002 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 546 | 2014 |
| Identification and manipulation of tumor associated macrophages in human cancers M Heusinkveld, SH van Der Burg Journal of translational medicine 9, 1-14, 2011 | 529 | 2011 |
| Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. SH Van Der Burg, MJ Visseren, RM Brandt, WM Kast, CJ Melief Journal of immunology (Baltimore, Md.: 1950) 156 (9), 3308-3314, 1996 | 521 | 1996 |
| Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine MJP Welters, GG Kenter, SJ Piersma, APG Vloon, MJG Löwik, ... Clinical Cancer Research 14 (1), 178-187, 2008 | 485 | 2008 |
| High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage … SJ Piersma, ES Jordanova, MIE Van Poelgeest, KMC Kwappenberg, ... Cancer research 67 (1), 354-361, 2007 | 485 | 2007 |
| Neoantigen landscape dynamics during human melanoma–T cell interactions EME Verdegaal, NFCC De Miranda, M Visser, T Harryvan, ... Nature 536 (7614), 91-95, 2016 | 470 | 2016 |
| Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response P Kvistborg, D Philips, S Kelderman, L Hageman, C Ottensmeier, ... Science translational medicine 6 (254), 254ra128-254ra128, 2014 | 420 | 2014 |
| Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial E Massarelli, W William, F Johnson, M Kies, R Ferrarotto, M Guo, L Feng, ... JAMA oncology 5 (1), 67-73, 2019 | 408 | 2019 |
| Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6 A de Jong, MIE van Poelgeest, JM van der Hulst, JW Drijfhout, GJ Fleuren, ... Cancer research 64 (15), 5449-5455, 2004 | 402 | 2004 |
| Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low … GG Kenter, MJP Welters, ARPM Valentijn, MJG Löwik, ... Clinical cancer research 14 (1), 169-177, 2008 | 387 | 2008 |
| M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells M Heusinkveld, PJ de Vos van Steenwijk, R Goedemans, ... The Journal of Immunology 187 (3), 1157-1165, 2011 | 368 | 2011 |
